Article Information
History
- September 22, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Daniel Zaidman1,*,
- Paul Gehrtz1,*,
- Mihajlo Filep1,
- Daren Fearon2,
- Jaime Prilusky3,
- Shirly Duberstein4,
- Galit Cohen4,
- David Owen2,5,
- Efrat Resnick1,
- Claire Strain-Damerell2,5,
- Petra Lukacik2,5,
- Covid-Moonshot Consortium,
- Haim Barr4,
- Martin A. Walsh2,5,
- Frank von Delft2,5,6,7 and
- Nir London1,#
- 1Dept. of Organic Chemistry, Weizmann Institute of Science, 7610001, Rehovot, Israel
- 2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K
- 3Life Sciences Core Facilities, Weizmann Institute of Science, 7610001, Rehovot, Israel
- 4Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot, 7610001, Israel
- 5Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, U.K
- 6Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, OX3 7DQ, UK
- 7Department of Biochemistry, University of Johannesburg, Auckland Park 2006, South Africa
- ↵#Corresponding author: nir.london{at}weizmann.ac.il
↵* Equal contribution
Posted September 22, 2020.
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor
